Literature DB >> 16690908

The immune response during hepatitis B virus infection.

Antonio Bertoletti1, Adam J Gehring.   

Abstract

Hepatitis B virus (HBV) is a major cause of chronic liver inflammation worldwide. Recent knowledge of the virological and immunological events secondary to HBV infection has increased our understanding of the mechanisms involved in viral clearance and persistence. In this review, how the early virological and immunological events might influence the development of a coordinate activation of adaptive immunity necessary to control HBV infection is analysed. The mechanism(s) by which high levels of viral antigens, liver immunological features, regulatory cells and dendritic cell defects might maintain the HBV-specific immunological collapse, typical of chronic hepatitis B patients, is also examined.

Entities:  

Mesh:

Year:  2006        PMID: 16690908     DOI: 10.1099/vir.0.81920-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  116 in total

1.  Enhancing the antihepatitis B virus immune response by adefovir dipivoxil and entecavir therapies.

Authors:  Yanfang Jiang; Wanyu Li; Lei Yu; Jingjing Liu; Guijie Xin; Hongqing Yan; Pinghui Sun; Hong Zhang; Damo Xu; Junqi Niu
Journal:  Cell Mol Immunol       Date:  2010-10-04       Impact factor: 11.530

2.  Parallel decline of CD8+CD38+ lymphocytes and viremia in treated hepatitis B patients.

Authors:  Wei Cao; Zhi-Feng Qiu; Tai-Sheng Li
Journal:  World J Gastroenterol       Date:  2011-05-07       Impact factor: 5.742

3.  Different effect of HBV vaccine after liver transplantation between chronic HBV carriers and non-HBV patients who received HBcAb-positive grafts.

Authors:  Masatoshi Ishigami; Hideya Kamei; Taro Nakamura; Yoshiaki Katano; Hisami Ando; Tetsuya Kiuchi; Hidemi Goto
Journal:  J Gastroenterol       Date:  2010-09-11       Impact factor: 7.527

4.  Noninvasive measurement of liver fibrosis by transient elastography and influencing factors in patients with chronic hepatitis B-A single center retrospective study of 466 patients.

Authors:  Hongfang Ding; Ting Wu; Ke Ma; Xiaojing Wang; Zeguang Wu; Wei Guo; Junying Qi; Qin Ning
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-01-27

5.  Restoration of TLR3-activated myeloid dendritic cell activity leads to improved natural killer cell function in chronic hepatitis B virus infection.

Authors:  Eric T T L Tjwa; Gertine W van Oord; Paula J Biesta; Andre Boonstra; Harry L A Janssen; Andrea M Woltman
Journal:  J Virol       Date:  2012-02-08       Impact factor: 5.103

6.  Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis.

Authors:  Gregor Ebert; Cody Allison; Simon Preston; James Cooney; Jesse G Toe; Michael D Stutz; Samar Ojaimi; Nikola Baschuk; Ueli Nachbur; Joseph Torresi; John Silke; C Glenn Begley; Marc Pellegrini
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-20       Impact factor: 11.205

7.  Proteasomes regulate hepatitis B virus replication by degradation of viral core-related proteins in a two-step manner.

Authors:  Zi-Hua Zheng; Hui-Ying Yang; Lin Gu; Xiao-Mou Peng
Journal:  Virus Genes       Date:  2016-04-22       Impact factor: 2.332

8.  Serum levels of B-cell activating factor in chronic hepatitis B virus infection: association with clinical diseases.

Authors:  Cuiling Yang; Na Li; Yawen Wang; Pingping Zhang; Qianqian Zhu; Fang Li; Qunying Han; Yi Lv; Ling Yu; Ping Wei; Zhengwen Liu
Journal:  J Interferon Cytokine Res       Date:  2014-05-08       Impact factor: 2.607

9.  Molecular mechanisms of HBeAg in persistent HBV infection.

Authors:  Li-Min Chen; Xue-Gong Fan; Jing Ma; Bo He; Yong-Fang Jiang
Journal:  Hepatol Int       Date:  2016-05-18       Impact factor: 6.047

10.  Effect of viral load on T-lymphocyte failure in patients with chronic hepatitis B.

Authors:  Jing You; Hutcha Sriplung; Alan Geater; Virasakdi Chongsuvivatwong; Lin Zhuang; Hong-Ying Chen; Lan Yu; Bao-Zhang Tang; Jun-Hua Huang
Journal:  World J Gastroenterol       Date:  2008-02-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.